What is HC Wainwright’s Forecast for NERV Q1 Earnings?

Minerva Neurosciences, Inc (NASDAQ:NERV) – Analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Minerva Neurosciences in a research report issued on Thursday, March 12th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings of ($0.11) per share for the quarter. HC Wainwright has a “Neutral” rating and a $7.00 price objective on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.12) EPS, Q4 2027 earnings at ($0.13) EPS, FY2029 earnings at $0.63 EPS and FY2030 earnings at $1.71 EPS.

Several other brokerages also recently commented on NERV. Wall Street Zen raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Monday, December 29th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $7.00.

Minerva Neurosciences Stock Up 1.8%

NASDAQ NERV opened at $7.83 on Friday. The company has a market capitalization of $338.84 million, a price-to-earnings ratio of -0.29 and a beta of -0.31. Minerva Neurosciences has a twelve month low of $1.15 and a twelve month high of $12.46. The stock has a fifty day simple moving average of $5.49 and a 200 day simple moving average of $4.07.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.75.

Hedge Funds Weigh In On Minerva Neurosciences

Hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in Minerva Neurosciences during the fourth quarter worth $36,000. State Street Corp boosted its position in Minerva Neurosciences by 45.4% during the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 7,500 shares during the last quarter. Apella Capital LLC boosted its position in Minerva Neurosciences by 87.8% during the third quarter. Apella Capital LLC now owns 39,314 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 18,375 shares during the last quarter. Millennium Management LLC acquired a new stake in Minerva Neurosciences during the 4th quarter worth about $554,000. Finally, Renaissance Technologies LLC raised its position in shares of Minerva Neurosciences by 28.1% in the 4th quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after acquiring an additional 32,700 shares in the last quarter. Institutional investors own 34.56% of the company’s stock.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.